Runners crossing the finish line at a prostate cancer awareness run

Prostate cancer

Also called prostate carcinoma, PSA, prostate adenocarcinoma, BRCA2

The second most common cancer in men worldwide. Many cases grow slowly and can be safely watched; MRI, genetic testing, and newer drugs have reshaped diagnosis and treatment.

Updated 5 sources

Photo: Army HRC (Public domain)

This entry is a draft and is still being reviewed.

Types

  • Adenocarcinoma — nearly all prostate cancers1.
  • By risk group: low-risk cancers that may never cause harm, intermediate-risk, high-risk, and metastatic disease1.
  • Castration-sensitive vs. castration-resistant — whether advanced cancer still responds to lowering testosterone1.
  • Rare types include neuroendocrine (small-cell) prostate cancer1.

Prevention

  • There's no proven way to prevent prostate cancer. Screening aims to find dangerous cancers early without overtreating harmless ones2.
  • For men 55 to 69, the USPSTF recommends deciding about PSA screening individually after discussing benefits and harms with a clinician; it recommends against routine screening at 70 and older2.

Risk factors

  • Older age — the strongest risk factor1
  • A father or brother with prostate cancer1
  • Black ancestry — higher rates and higher death rates1,2
  • Inherited gene variants, especially BRCA24

Diagnostics

  • PSA blood test — a screening signal, not a diagnosis; PSA also rises with benign enlargement and inflammation2.
  • MRI before biopsy — in the PRECISION trial, MRI-targeted biopsy found more clinically significant cancers (38% vs. 26%) and fewer insignificant ones than standard biopsy3.
  • Biopsy graded with the Gleason score, reported as Grade Group 1 to 51.
  • Staging scans such as PSMA PET for higher-risk cancer1.

Treatments

  • Active surveillance for low-risk cancer: regular PSA tests, MRI, and repeat biopsies, treating only if the cancer progresses1.
  • Surgery (radical prostatectomy) or radiation therapy for localized cancer that needs treatment1.
  • In the ProtecT trial, about 2–3% of men died of prostate cancer over 15 years whether they had monitoring, surgery, or radiation. Monitoring led to more spread, but not more deaths; surgery and radiation caused more urinary and sexual side effects5.
  • Hormone therapy (androgen deprivation) combined with newer drugs for advanced cancer1.

Molecular Biomarkers

  • PSA, along with PSA density and free PSA1.
  • Blood and urine tests such as the Prostate Health Index (PHI), 4Kscore, and PCA3 help decide who needs a biopsy1.
  • Gleason score / Grade Group from biopsy tissue1.
  • Tissue genomic tests can refine risk in localized cancer1.
  • In advanced cancer, tumors are tested for DNA-repair defects such as BRCA1, BRCA2, and ATM changes, and for mismatch-repair deficiency, which make targeted drugs or immunotherapy an option1,4.

Genes

  • About 12% of men with metastatic prostate cancer carry an inherited DNA-repair gene mutation, most often BRCA2, followed by CHEK2, ATM, and BRCA14.
  • Germline genetic testing is now recommended for men with metastatic prostate cancer; results also tell relatives about their own cancer risk.
  • Variants in HOXB13 also raise risk.

Lifestyle

  • No lifestyle change is proven to prevent prostate cancer.
  • Staying active and keeping a healthy weight support overall health and help offset side effects of hormone therapy, such as bone and muscle loss.
  • Men on active surveillance should keep every scheduled check-up1.

Nutrition

  • No diet or supplement is proven to prevent prostate cancer.
  • Large trials of selenium and vitamin E supplements found no protective benefit, and vitamin E slightly increased risk.

Medical Interventions

  • Radical prostatectomy, usually robot-assisted1
  • External-beam radiation or brachytherapy (radioactive seeds)1
  • Focal therapies such as high-intensity focused ultrasound in selected cases1

Pharmaceutical Drugs

  • Androgen deprivation therapy: leuprolide, goserelin, degarelix, relugolix1
  • Androgen receptor pathway inhibitors: abiraterone, enzalutamide, apalutamide, darolutamide1
  • Chemotherapy: docetaxel, cabazitaxel1
  • PARP inhibitors: olaparib, rucaparib for cancers with DNA-repair defects1,4
  • Radioligand therapy: lutetium-177 PSMA-617 for PSMA-positive metastatic castration-resistant cancer
  • Bone-targeted therapy: radium-223, denosumab, zoledronic acid1
  • Immunotherapy: pembrolizumab for mismatch-repair–deficient tumors1

Sources

  1. Rebello RJ, Oing C, Knudsen KE, et al. Prostate cancer. Nat Rev Dis Primers. 2021;7(1):9. doi:10.1038/s41572-020-00243-0
  2. US Preventive Services Task Force; Grossman DC, Curry SJ, et al. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. JAMA. 2018;319(18):1901-1913. doi:10.1001/jama.2018.3710
  3. Kasivisvanathan V, Rannikko AS, Borghi M, et al. MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med. 2018;378(19):1767-1777. doi:10.1056/NEJMoa1801993
  4. Pritchard CC, Mateo J, Walsh MF, et al. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N Engl J Med. 2016;375(5):443-453. doi:10.1056/NEJMoa1603144
  5. Hamdy FC, Donovan JL, Lane JA, et al. Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med. 2023;388(17):1547-1558. doi:10.1056/NEJMoa2214122

This page summarizes published research for education. It isn't medical advice and doesn't replace care from a clinician who knows your history. Never start, stop, or change a medication without talking to your prescriber.